A Pilot Study of the Combination of Entinostat with Capecitabine in Advanced Breast Cancer

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left" colspan="4">Combination designation</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left" rowspan="2">Entinostat</td><td class="align_center">5 mg</td><td class="align_center">Combination 2</td><td class="align_center">Combination 4</td></tr><tr><td class="align_center">3 mg</td><td class="align_center">Combination 1</td><td class="align_center">Combination 3</td></tr><tr><td class="align_left" colspan="2" rowspan="2"></td><td class="align_center">800 mg/m<sup>2</sup></td><td class="align_center">1000 mg/m<sup>2</sup></td></tr><tr><td class="align_center" colspan="2">Capecitabine</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Dose combinations studied in the pilot trial.</div>

International Journal of Breast Cancer

tab1

Table 1

Table 1: A Pilot Study of the Combination of Entinostat with Capecitabine in Advanced Breast Cancer 